Morphoproteomic analysis (Figure 1) of the bone specimen (metastases) revealed expression of p-ERK1/2 (variable expression [1-3%] of the RAS/RAF kinase/extracellular signal–regulated kinase ERK pathway, as evidenced by the cytoplasmic expression and nuclear translocation of p-ERK1/2 in more than 80% of the tumor cells), p-mTOR pathway activation, HSP90 expression, moderate expression of TRAIL and NESTIN expression. The gene discussed is MTOR; the disease is neoplasm.